NCT02460198 is a phase II study conducted on 124 previously treated patients with locally advanced unresectable or metastatic dMMR/MSI-H CRC (cohort A: standard therapies including fluoropyrimidine, oxaliplatin, and irinotecan; cohort B: fluoropyrimidine + oxaliplatin or fluoropyrimidine + irinotecan, with or without anti-VEGF/EGFR monoclonal antibody) (23). The gene discussed is VEGFA; the disease is colorectal carcinoma.